Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Columbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
J Allergy Clin Immunol. 2023 Jun;151(6):1429-1447. doi: 10.1016/j.jaci.2023.03.026. Epub 2023 Apr 24.
Type 1 diabetes (T1D) is a polygenic disease and does not follow a mendelian pattern. Inborn errors of immunity (IEIs), on the other hand, are caused by damaging germline variants, suggesting that T1D and IEIs have nothing in common. Some IEIs, resulting from mutations in genes regulating regulatory T-cell homeostasis, are associated with elevated incidence of T1D. The genetic spectrum of IEIs is gradually being unraveled; consequently, molecular pathways underlying human monogenic autoimmunity are being identified. There is an appreciable overlap between some of these pathways and the genetic variants that determine T1D susceptibility, suggesting that after all, IEI and T1D are 2 sides of the same coin. The study of monogenic IEIs with a variable incidence of T1D has the potential to provide crucial insights into the mechanisms leading to T1D. These insights contribute to the definition of T1D endotypes and explain disease heterogeneity. In this review, we discuss the interconnected pathogenic pathways of autoimmunity, β-cell function, and primary immunodeficiency. We also examine the role of environmental factors in disease penetrance as well as the circumstantial evidence of IEI drugs in preventing and curing T1D in individuals with IEIs, suggesting the repositioning of these drugs also for T1D therapy.
1 型糖尿病(T1D)是一种多基因疾病,不符合孟德尔模式。另一方面,先天性免疫缺陷(IEI)是由破坏性的种系变异引起的,这表明 T1D 和 IEI 没有任何共同之处。一些 IEI 是由调节调节性 T 细胞稳态的基因中的突变引起的,与 T1D 的发病率升高有关。IEI 的遗传谱逐渐被揭示;因此,正在确定人类单基因自身免疫的分子途径。其中一些途径与决定 T1D 易感性的遗传变异有明显的重叠,这表明 IEI 和 T1D 毕竟是同一枚硬币的两面。研究具有可变 T1D 发病率的单基因 IEI 有可能为导致 T1D 的机制提供重要的见解。这些见解有助于确定 T1D 的表型,并解释疾病异质性。在这篇综述中,我们讨论了自身免疫、β 细胞功能和原发性免疫缺陷的相互关联的致病途径。我们还研究了环境因素在疾病易感性中的作用以及 IEI 药物在预防和治疗具有 IEI 的个体的 T1D 中的间接证据,这表明这些药物也可以重新定位用于 T1D 治疗。